Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Gregory Quinlan

Nurse Practitioner Brockton, MA Nurse Practitioner

NPI 1588628333 CMS profile 11064141

235 N Pearl St, Brockton, MA 02301

Open in the dashboard

General payments

$6,623

325 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gregory Quinlan of Brockton, MA is reported in the CMS Open Payments database as having received $6,623 across 325 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,935 89
2024 General $2,072 97
2023 General $1,698 88
2022 General $859 47
2021 General $60 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gregory Quinlan
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Gregory Quinlan were reported at $1,935. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Gregory Quinlan Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $60 $135 $40–$426 $132
2022 $859 $152 $48–$470 $149
2023 $1,698 $166 $54–$529 $160
2024 $2,072 $173 $55–$556 $164
2025 $1,935 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $1,164 87 payments
  2. E.R. Squibb & Sons, L.L.C. $1,163 41 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $420 17 payments
  4. Amgen Inc. $417 17 payments
  5. Scpharmaceuticals Inc. $375 20 payments
  6. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $368 20 payments
  7. Merck Sharp & Dohme Corporation $356 20 payments
  8. Pfizer Inc. $334 18 payments
  9. Janssen Pharmaceuticals, Inc $295 12 payments
  10. Alnylam Pharmaceuticals Inc. $277 11 payments
  11. Other $1,455 62 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,623 325 payments
Products named General payments · program years 2021–2025
  1. LEQVIO $830 55 payments
  2. ELIQUIS $655 24 payments
  3. CAMZYOS $508 17 payments
  4. VERQUVO $473 26 payments
  5. FUROSCIX $375 20 payments
  6. Repatha $371 15 payments
  7. ENTRESTO $368 31 payments
  8. LifeVest $368 20 payments
  9. JARDIANCE $309 12 payments
  10. Arcalyst $303 10 payments
  11. Other $2,773 138 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$21,633

Medicare's payments for the services billed

Medicare patients

281

Average age 76

Services billed

542

145 women, 136 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 61%
Arthritis 52%
Heart failure 51%
Atrial fibrillation 48%
Diabetes 46%
Chronic kidney disease 42%
COPD 35%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $242
$242 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $193
$193 — —
Repatha
  • Amgen Inc. $151
$151 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $151
$151 — —
FUROSCIX
  • SCPHARMACEUTICALS INC. $150
$150 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

325 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record